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10.Hypertension is a risk factor for both progression of atrial fibrillation (AF) and develop-
ment of AF-related complications, that is major adverse cardiac and cerebrovascular
events (MACCE). It is unknown whether left ventricular hypertrophy (LVH) as a conse-
quence of hypertension is also a risk factor for both these end points. We aimed to assess
this in low-risk AF patients, also assessing gender-related differences. We included 799
patients from the Euro Heart Survey with nonvalvular AF and a baseline echocardio-
gram. Patients with and without hypertension were included. End points after 1 year were
occurrence of AF progression, that is paroxysmal AF becoming persistent and/or perma-
nent AF, and MACCE. Echocardiographic LVH was present in 33% of 379 hypertensive
patients. AF progression after 1 year occurred in 10.2% of 373 patients with rhythm fol-
low-up. In hypertensive patients with LVH, AF progression occurred more frequently as
compared with hypertensive patients without LVH (23.3% vs 8.8%, p = 0.011). In hyper-
tensive AF patients, LVH was the most important multivariably adjusted determinant of
AF progression on multivariable logistic regression (odds ratio 4.84, 95% confidence
interval 1.70 to 13.78, p = 0.003). This effect was only seen in male patients (27.5% vs
5.8%, p = 0.002), while in female hypertensive patients, no differences were found in AF
progression rates regarding the presence or absence of LVH (15.2% vs 15.0%, p = 0.999).
No differences were seen in MACCE for hypertensive patients with and without LVH. In
conclusion, in men with hypertension, LVH is associated with AF progression. This associ-
ation seems to be absent in hypertensive women. © 2018 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license. (http://
creativecommons.org/licenses/by-nc-nd/4.0/) (Am J Cardiol 2018;122:578583)iversity Medical Center (MUMC+), Department of Car-
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1016/j.amjcard.2018.04.053Atrial fibrillation (AF) is associated with several co-mor-
bidities, the most prevalent being hypertension, affecting
49% to 90% of AF patients.1 Hypertension is a risk factor
for both the development2 and the progression of AF.3,4
Moreover, hypertension is a risk factor for the development
of AF-related complications, such as major adverse cardiac
and cerebrovascular events (MACCE).5 Paroxysmal AF
progresses to persistent or permanent AF in 8.6% to 22% of
patients after 1 year, depending on the underlying co-mor-
bidities.6,7 AF progression is not merely an arrhythmic phe-
nomenon, but it is also associated with a higher rate of
ischemic stroke, that is 2% to 4% per year for paroxysmal,
persistent and permanent AF, respectively.8 Furthermore,
AF progression has been associated with hospitalization
and all-cause mortality in a primary care study.9 Although
the relation of hypertension with AF progression and
MACCE is clearly established, it is unknown whether
hypertensive end organ damage, that is left ventricular
hypertrophy (LVH), is also associated with these end points
and whether this differs across gender. We hypothesized
patients with LVH as a result of hypertension show more
AF progression and subsequent occurrence of MACCE
compared with hypertensive AF patients without LVH and
nonhypertensive patients. Furthermore, we aimed to inves-
tigate whether this differs across gender.
Figure 1. Differences in AF progression and MACCE rates after 1 year of
follow-up for patients with and without hypertension.
AF = atrial fibrillation; MACCE =major adverse cardiac and cerebrovascu-
lar events.
Arrhythmias and Conduction Disturbances /LVH and AF Progression 579Methods
A detailed description of the methods and results of the
Euro Heart Survey (EHS) on AF has previously been pub-
lished.10,11 In summary, the EHS is a prospective registry
conducted 2003 to 2005 in 182 hospitals across 35 member
countries of the European Society of Cardiology. All cen-
ters obtained approval from their Institutional Committee
on Human Research. Consecutive in and outpatients with
(Holter) electrocardiogram proved AF were included after
providing written informed consent. One-year follow-up
was completed in 3,978 of the included 5,333 patients.
We included 799 patients from the EHS with nonvalvular,
paroxysmal AF, and a baseline echocardiogram. Patients
with and without hypertension were selected. Since we
aimed to assess the relation of hypertension and LVH with
the end points of AF progression and MACCE, we tried to
diminish the influence of other factors related to these end
points as much as possible. This was done by excluding
patients with other stroke risk factors, that is congestive heart
failure, age 65 years, diabetes mellitus, previous stroke
and/or transient ischemic attack, and vascular disease.
The occurrence of AF progression and MACCE after 1
year was assessed separately for the groups with and with-
out hypertension, subdivided by the presence of echocar-
diographic LVH. Gender differences were also evaluated.
Hypertension was defined as the presence of systolic blood
pressure (BP) at rest of >140 mm Hg or diastolic BP of
>90 mm Hg on 2 occasions or current antihypertensive
drug treatment. The presence or absence of echocardio-
graphic LVH was assessed by the treating physician. AF
progression was defined as paroxysmal AF at baseline
becoming persistent or permanent AF after 1 year of fol-
low-up, like previously defined by de Vos et al4 and
MACCE was defined as cardiovascular death, stroke, tran-
sient ischemic attack, systemic thromboembolism, myocar-
dial infarction, or major bleeding (hemorrhagic stroke or
bleeding requiring hospitalization, causing a hemoglobin
level decrease of 2 g/l or requiring blood transfusion).
Patients with missing data were excluded and a complete-
case analysis was performed.
Data were analyzed with SPSS statistical software (ver-
sion 22.0, SPSS Inc., Chicago, Illinois). Continuous varia-
bles are reported as mean § standard deviation if normally
distributed and as median and inter quartile range if not.
Normally distributed continuous variables were compared
between groups using the independent samples t test,
whereas not normally distributed continuous variables were
compared using the MannWhitney U test. Categorical
variables are reported as observed number of patients and
percentage. Amonggroup comparisons were made using a
chi-square test. Fisher’s exact test was used in case of any
expected cell count <5. All baseline characteristics with a
significant univariate association (p <0.10) with one of the
end points were incorporated into a multivariable logistic
regression model with stepwise reduction of the model by
excluding variables with p >0.10. All variables in the final
model were tested for interactions. Remaining variables
with p <0.05 were considered significant independent
determinants for the end points of AF progression and the
occurrence of MACCE.Results
Of the 799 included patients, rhythm follow-up was
available in 47% and information on the occurrence of
MACCE in 76%. The majority of the patients was men
(73%), mean age was 52 § 10 years. AF progression
occurred in 38 (10.2%) of 373 patients, whereas MACCE
occurred in 21 (3.4%) of 610 patients. Hypertension was
present in 47%. In general, hypertensive AF patients
showed more AF progression (14.2% vs 7.1%, p = 0.025)
as well as MACCE (5.3% vs 1.8%, p = 0.018), compared
with the normotensives (Figure 1).
LVH was present in 124 (33%) of 379 hypertensive
patients and in 51 (12%) of 420 normotensive AF patients.
The baseline characteristics of the included patients, subdi-
vided by the presence of hypertension and LVH, are pre-
sented in Table 1, together with the occurrence of the end
points for all groups. In patients without hypertension, no
differences in AF progression and in the development of
MACCE could be ascertained when comparing patients
with LVH to those without (Figure 2).
Hypertensive patients with echocardiographic LVH at
baseline (124 of 379) had on average a higher body mass
index and were more frequently on calcium antagonist and
angiotensin converting enzyme inhibitors, compared with
hypertensive patients without LVH (Table 1). AF progres-
sion at 1 year was significantly more prevalent in patients
with LVH (23.3% vs 8.8%, p = 0.011), whereas no differen-
ces were found in the development of MACCE (4.5% vs
5.7%, p = 0.782; Figure 2).
Several determinants of AF progression were identified
using multivariable analysis in the patients with hyperten-
sion, the most important being LVH on echocardiography
(Table 2). Other independent determinants of AF progres-
sion were the use of vitamin K antagonists, age, and dia-
stolic BP. No interactions were present. In hypertensive
men, AF progression rates were 27.5% and 5.8% per year
in those with and without LVH, respectively, similar to the
rates seen in the studied overall cohort. In hypertensive
women however, AF progression rates in patients with
and without LVH did not differ, that is 15.2% versus
15.0%, p = 0.999 (Figure 3). Development of MACCE
after 1 year did not differ between men with LVH vs
without (3.2% vs 6.1%, p = 0.507), and in women (7.4%
vs 5.0%, p = 0.644).
Figure 2. Differences in AF progression and MACCE rates after 1 year for
patients with and without hypertension, subdivided by presence of LVH.
AF = atrial fibrillation; LVH =l eft ventricular hypertrophy;
MACCE =major adverse cardiac and cerebrovascular events. * = statistical
significance.
Table 1
Baseline characteristics and the occurrence of end points for atrial fibrillation patients with and without hypertension, subdivided by the presence of left ven-
tricular hypertrophy on echocardiography
Variable Systemic hypertension
Yes (n = 379) No (n = 420)
No LVH
(n = 255)
LVH
(n = 124)
p value No LVH
(n = 369)
LVH
(n = 51)
p value
Age (years) 56 § 8 55 § 8 0.277 50 § 11 52§ 9 0.045
Women 80 (31%) 33 (27%) 0.342 94 (26%) 10 (20%) 0.363
Systolic blood pressure 142 § 21 144 § 23 0.388 125 § 15 128 § 16 0.281
Diastolic blood pressure 88 § 13 88 § 13 0.628 78 § 10 79§ 12 0.426
Ventricular rate on qualifying electrocardiogram 111 § 33 109 § 31 0.658 109 § 31 108 § 35 0.874
Body mass index (kg/m2) 27.8 § 4.2 28.9 § 3.7 0.019 26.4 § 3.9 28.0 § 4.5 0.008
Left ventricular ejection fraction (%) 55 § 13 53 § 13 0.159 56 § 13 56§ 14 0.989
Left atrial diameter (mm) 42 § 7 46 § 8 0.001 41 § 8 42§ 10 0.449
Left atrial diameter index (mm/m2) 22 § 4 22 § 3 0.253 21 § 4 21§ 5 0.858
Mitral regurgitation grade 2 and higher 68 (27%) 30 (24%) 0.606 61 (17%) 13 (26%) 0.115
Aortic regurgitation grade 2 and higher 21 (8%) 11 (9%) 0.843 14 (4%) 5 (10%) 0.067
Aortic stenosis* 3 (1.2%) 6 (4.8%) 0.064 2 (0.5%) 2 (3.9%) 0.074
Hyperlipidemiay 83 (34%) 35 (29%) 0.407 68 (19%) 13 (27%) 0.215
Valvular heart disease 17 (7%) 13 (11%) 0.213 28 (8%) 7 (14%) 0.171
Chronic obstructive pulmonary disease 17 (7%) 12 (10%) 0.285 10 (2.7%) 2 (3.9%) 0.647
Renal failure 4 (1.6%) 4 (3.2%) 0.448 0 1 (2.0%) 0.121
Hypothyroidism 13 (5.5%) 6 (5.3%) 0.946 11 (3.2%) 1 (2.0%) 0.999
Hyperthyroidism 15 (6.4%) 3 (2.7%) 0.141 19 (5.5%) 3 (6.1%) 0.745
Current smoker 47 (19%) 28 (23%) 0.302 87 (24%) 4 (8%) 0.009
Current alcohol drinker (1/week) 154 (64%) 65 (57%) 0.181 209 (62%) 26 (53%) 0.240
Medications
Vitamin K antagonist 160 (65%) 70 (57%) 0.155 206 (60%) 26 (52%) 0.301
Beta blocker 29 (12%) 16 (13%) 0.736 12 (3.5%) 4 (8.0%) 0.131
Angiotensin converting enzyme inhibitor 129 (52%) 84 (68%) 0.004 43 (13%) 14 (28%) 0.003
Angiotensin receptor blockers 44 (18%) 21 (17%) 0.847 10 (2.9%) 1 (2.0%) 0.999
Dihydropiridine calcium channel blocker 25 (10%) 33 (27%) 0.001 5 (1.4%) 2 (4.0%) 0.218
Diuretic 82 (33%) 46 (37%) 0.440 24 (7%) 4 (8%) 0.768
Any anti-arrhythmic drug 148 (58 %) 64 (52%) 0.237 211 (57%) 34 (67%) 0.198
Atrial fibrillation progression at 1 year follow-up (n = 373) 9 (9%) 14 (23%) 0.011 13 (6.8%) 2 (9.5%) 0.649
Major adverse cardiac and cerebrovascular events at 1 year follow-up (n = 610) 11 (5.7%) 4 (4.5%) 0.782 5 (1.7%) 1 (2.9%) 0.494
*Aortic stenosis was defined as progressive narrowing of the aortic valve resulting in the obstructed passage of blood from the left ventricle into the aorta.
yHyperlipidemia was defined as fasting total cholesterol >240 mg/dl (6.2 mmol/l) or LDL-cholesterol >160 mg/dl (4.1 mmol/l) or treatment with any lipid
lowering drugs.
580 The American Journal of Cardiology (www.ajconline.org)In male patients with hypertension, the only independent
determinant of AF progression was LVH (OR 6.16, 95% CI
1.81 to 20.99, p = 0.004). For female patients, independent
determinants were age (OR 1.28 for increments of 1 year,
95% CI 1.02 to 1.61, p =0 .036), and diastolic BP (OR 0.93
for increments of 1 mm Hg, 95% CI 0.87 to 0.99,
p = 0.029). In both hypertensive men and women, the use
of VKA was not a determinant for AF progression, in con-
trast to the overall population. The difference between men
and women who were prescribed vitamin K antagonists
was statistically significant in the hypertensive patients
(66% vs 53%, p = 0.017), but not in the normotensives
(61% vs 53%, p = 0.178).Discussion
Almost half of the patients in our cohort had a history of
hypertension. These patients showed more often AF
Table 2
Univariable and multivariable regression for progression of atrial fibrillation in hypertensive patients
Variable Univariable regression Multivariable regression
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Left ventricular hypertrophy 3.15 (1.27-7.80) 0.013 4.84 (1.70-13.78) 0.003
Vitamin K antagonist 2.71 (1.04-7.08) 0.041 3.72 (1.28-10.83) 0.016
Age 1.11 (1.02-1.20) 0.016 1.13 (1.04-1.24) 0.007
Diastolic blood pressure, per mm Hg increase 0.96 (0.93-1.00) 0.058 0.95 (0.91-0.99) 0.017
Left atrial diameter, corrected for body surface area 1.12 (0.99-1.27) 0.076
Arrhythmias and Conduction Disturbances /LVH and AF Progression 581progression and MACCE after 1 year compared with
patients without hypertension (Figure 1), in accordance
with previous data.3,5,12 LVH at baseline was present in a
third of the patients with hypertension. As hypothesized, a
significantly larger proportion of these patients showed AF
progression after 1 year when compared with hypertensive
patients without LVH on echocardiographic assessment
(Figure 2). Recently, Padfield et al have also shown that
LVH is one of the determinants of AF progression after a
median follow-up of 6 years.13 Moreover, the higher pro-
gression rate seen in patients with hypertension, could be
mainly driven by LVH, since AF progression rates in
hypertensive patients without LVH and nonhypertensive
patients were comparable (Figure 2). Even after correcting
for other factors, LVH remained the most important inde-
pendent determinant of AF progression in the hypertensive
group. Thus, LVH seems to be a key marker for AF pro-
gression in hypertensive patients with low-risk AF. How-
ever, a difference in the occurrence of MACCE could not
be ascertained in these patients, possibly due to the overall
low MACCE-rate in this relatively low-risk AF population
and follow-up duration of 1 year. In addition, 60% of the
patients were on vitamin K antagonists, probably reducing
MACCE rates.14
It is unknown whether this effect of LVH on AF progres-
sion is reversible. Hennersdorf et al15 have shown that the
prevalence of paroxysmal AF can be diminished in patients
with regression of LVH by treating hypertension, compared
with patients with a progression in LVH despite treatment.
In that post hoc analysis, 24-hour Holter electrocardiograms
were performed at baseline and after a mean of 2 years of
antihypertensive treatment. The short time span covered by
these Holter electrocardiograms and the absence of a prede-
fined scheme for rhythm follow-up, makes cautiousFigure 3. AF progression rates after 1 year of male and female hyperten-
sive AF patients in absence and presence of LVH.
AF = atrial fibrillation; LVH = left ventricular hypertrophy.interpretation of these data necessary. However, a similar
reduction in AF progression rates could possibly be
achieved by adequate treatment of hypertension leading to
regression of LVH. Of course, this should be studied in a
prospective and randomized manner to draw definite con-
clusions.
Other independent determinants of AF progression in
hypertensive AF patients were use of vitamin K antago-
nists, age, and diastolic BP. Age is a known risk factor for
AF progression and is incorporated in the HATCH-score
(Heart failure, Age, previous Transient ischemic attack or
stroke, Chronic obstructive pulmonary disease, and Hyper-
tension).3,4 The use of VKA however is not a known risk
factor for AF progression and the effect we observed may
be due to confounding. Since stroke risk scores were not in
use during the conduct of this registry, the decision to start
antithrombotic therapy was made at the discretion of the
treating physician. It is possible that this decision was based
on clinical parameters, such as left atrial diameter, left atrial
volume, and general health of the patient. An alternative
explanation may be that VKA are known to cause vascular
calcification in animal models.16 Since coronary artery cal-
cification in humans is associated with an increased risk of
the development of AF, this process may also be associated
with AF progression.17
The last independent determinant was diastolic BP. This
effect has not been reported in literature before. Although it
may be a chance finding, the protective effect of diastolic
BP might in part be explained by the relatively higher pulse
pressure in patients with a lower diastolic BP. Since a
higher pulse pressure is indicative of stiffness of the aorta
or major arteries and is related to vascular disease, it might
play a role in the progression of AF. Pulse pressure is a
known risk factor for new-onset AF, whereas in the same
study mean arterial pressure was not related to incident
AF.18 Furthermore, pulse pressure, and not mean arterial
pressure, was proved to be related to cardiovascular events
in older hypertensive patients.19 However, pulse pressure
was not a significant determinant in our analysis.
In patients without hypertension, LVH was present in a
smaller proportion and was not associated with AF progres-
sion and MACCE (Figure 2). These patients can be seen as
truly low-risk AF, with an overall AF progression rate of
7.1% and a MACCE rate of 1.8% per year, both represent-
ing a fairly low risk. However, this could be partially
caused by the small group of patients with LVH in the non-
hypertensive patients. Perhaps in a larger population, LVH
might lead to a higher AF progression rate through diastolic
dysfunction and an increase in left atrial diameter, even in
patients without hypertension.
582 The American Journal of Cardiology (www.ajconline.org)With respect to progression of AF in male and female
patients with hypertension, distinct differences were ascer-
tained regarding the effect of LVH (Figure 3). For male
patients with hypertension, the AF progression rates dif-
fered significantly for those with and without LVH, with
LVH being the only independent determinant of AF pro-
gression. However, in female patients, the progression rates
in patients with and without LVH were similar. So the dif-
ference in AF progression seen in the overall group with
hypertension is only attributable to the male patients,
whereas LVH does not seem to play a role in the progres-
sion of AF in female hypertensive patients.
The dissimilar effect of LVH on AF progression in men
and women could possibly be explained by the type of LVH.
A cardiovascular magnetic resonance imaging study in 741
patients by Rider et al has shown that male patients predomi-
nantly show concentric LVH, whereas female patients show
both concentric and eccentric LVH.20 In another study of 64
middle-aged women with at least 10 years of treatment for
hypertension, eccentric hypertrophy was more prevalent than
concentric hypertrophy on echocardiography (42% vs 5%, p
<0.001, mean age 54 years).21 In a post hoc analysis of the
AFFIRM (Atrial Fibrillation Follow-up Investigation of
Rhythm Management) trial, concentric LVH was found to be
associated with AF recurrences in the rhythm control arm,
whereas eccentric LVH was not associated with recur-
rences.22 This could be a consequence of diastolic dysfunc-
tion in concentric LVH, leading to elevation of filling
pressures and left atrial dilatation. It has been shown that con-
centric LVH has a more profound negative effect on left atrial
function and association with LA enlargement compared with
eccentric LVH,23 which could explain the effect seen on AF
recurrences in the AFFIRM trial. One could argue that con-
centric LVH might therefore also be associated with AF pro-
gression, explaining the dissimilar effect of LVH on AF
progression rates between genders in our population. Unfortu-
nately, we were not able to assess the type of LVH in our
population.
For female patients with hypertension, diastolic BP had
a protective effect on AF progression. No previous studies
have elaborated on this finding. However, Conen et al24
report a higher incidence of new-onset AF in middle-aged
women with a diastolic BP <65 mm Hg and suggest a U-
shaped association of diastolic BP and new-onset AF.
Unfortunately, no male control group was present in this
study.24 It is possible that a low diastolic BP could also be
associated with AF progression, like previously explained.
In conclusion, more research is needed regarding gender
differences in LVH and the progression of AF.
There are some limitations to the present study. First, we
performed a post hoc subgroup analysis of the EHS. There-
fore, the data presented in this study should be interpreted
with care. This study was conducted in 2003 to 2004, yet
the described outcomes are still relevant. Rhythm follow-up
was performed in 47% of the included patients and the dura-
tion of follow-up was 1 year, limiting the number of AF pro-
gression events. In addition, LVH was a dichotomous
parameter in the EHS, that is type of LVH was unknown
and wall thicknesses were not reported in mm. Furthermore,
some patients in the nonhypertensive group used medication
like an angiotensin converting enzyme inhibitor, angiotensinreceptor blocker, dihydropyridine calcium antagonist or a
diuretic. We were not able to assess whether these drugs
were prescribed for hypertension or for another indication.
Since in these patients hypertension was not checked as con-
comitant condition at time of conduct of the registry, they
were classified as nonhypertensive in the present study.
Last, women were underrepresented in this study.
In conclusion, in men with hypertension, LVH is associ-
ated with AF progression. This association seems to be
absent in hypertensive women.Disclosures
The investigators have no conflicts of interest to disclose.
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